Cannabis Effects on Driving Lateral Control With and Without Alcohol

Rebecca L. Hartman[a,b], Timothy L. Brown[c], Gary Milavetz[d], Andrew Spurgin[d], Russell S. Pierce[e], David A. Gorelick[a,f], Gary Gaffney[g], and Marilyn A. Huestis[a]

[a]Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, NIH, 251 Bayview Boulevard Ste 200 Rm 05A721, Baltimore, MD, USA; [b]Program in Toxicology, University of Maryland Baltimore, 660 West Redwood Street, Baltimore, MD, USA; [c]National Advanced Driving Simulator, University of Iowa, 2401 Oakdale Boulevard, Iowa City, IA, USA; [d]College of Pharmacy, University of Iowa, Iowa City, IA, USA; [e]VariableSolutions, USA; [f]Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA; [g]Carver College of Medicine, University of Iowa, Iowa City, IA, USA

Corresponding Author:

Professor Dr. Dr. (h.c.) Marilyn A. Huestis
Biomedical Research Center
Suite 200 Room 05A-721
251 Bayview Boulevard
Baltimore, MD 21224
mhuestis@intra.nida.nih.gov
443-740-2524 (phone)
443-740-2823 (fax)

Abstract

Background: Effects of cannabis, the most commonly encountered non-alcohol drug in driving under the influence cases, are heavily debated. We aimed to determine how blood Δ^9-tetrahydrocannabinol (THC) concentrations relate to driving impairment, with and without alcohol.

Methods: Current occasional (≥1x/last 3months, ≤3days/week) cannabis smokers drank placebo or low-dose alcohol, and inhaled 500mg placebo, low (2.9%)-THC, or high (6.7%)-THC vaporized cannabis over 10min *ad libitum* in separate sessions (within-subject design, 6 conditions). Participants drove (National Advanced Driving Simulator, University of Iowa) simulated drives (~0.8h duration). Blood, oral fluid (OF) and breath alcohol samples were collected before (0.17h, 0.42h) and after (1.4h, 2.3h) driving that occurred 0.5-1.3h after inhalation. We evaluated standard deviations of lateral position (lane weave, SDLP) and steering angle, lane departures/min, and maximum lateral acceleration.

Results: In N=18 completers (13 men, ages 21-37years), cannabis and alcohol increased SDLP. Blood THC concentrations of 8.2 and 13.1μg/L during driving increased SDLP similar to 0.05 and 0.08g/210L breath alcohol concentrations, the most common legal alcohol limits. Cannabis-alcohol SDLP effects were additive rather than synergistic, with 5μg/L THC+0.05g/210L alcohol showing similar SDLP to 0.08g/210L alcohol alone. Only alcohol increased lateral acceleration and the less-sensitive lane departures/min parameters. OF effectively documented cannabis exposure, although with greater THC concentration variability than paired blood samples.

Conclusions: SDLP was a sensitive cannabis-related lateral control impairment measure. During-drive blood THC ≥8.2μg/L increased SDLP similar to notably-impairing alcohol

concentrations. Despite OF's screening value, OF variability poses challenges in concentration-based effects interpretation.

Keywords: Cannabis, Alcohol, Driving, Lateral Control, THC, Oral Fluid

Clinical Trial Registration: Effects of Inhaled Cannabis on Driving Performance, NCT01620177

https://clinicaltrials.gov/ct2/show/NCT01620177?term=Cannabis+AND+driving&rank=1

1. Introduction

Reducing drugged driving is a US and worldwide priority (ONDCP, 2013). Cannabis is the most frequently detected illicit drug in drivers (Berning et al., 2015; Lacey et al., 2009; Legrand et al., 2013; Pilkinton et al., 2013); 12.6% of weekend nighttime drivers were positive for Δ^9-tetrahydrocannabinol (THC, primary psychoactive phytocannabinoid), in 2013-2014, a 48% increase since 2007 (Berning et al., 2015). Although blood THC is associated with increased crash risk and driver culpability (Asbridge et al., 2012; Drummer et al., 2004; Gjerde et al., 2011; Laumon et al., 2005; Li et al., 2012), cannabis effects on driving remain heavily debated. Road tracking and ability to remain within the lane are crucial driving skills. Lane weaving, an observable effect of drug-impaired driving, is a common measure for assessing driving performance. Standard deviation of lateral position (SDLP) is a sensitive vehicular control indicator, often employed in drugged driving research (Anderson et al., 2010; Lenné et al., 2010; Ramaekers et al., 2006a; Verster et al., 2006). In previous studies, cannabis increased SDLP and straddling lanes, but results were assessed by dose rather than blood THC concentrations (Ramaekers et al., 2000; Robbe, 1998; Downey et al., 2013).

To date, 23 states and the District of Columbia (DC) approved medical marijuana; 4 states and DC legalized recreational cannabis for adults (ProCon.org, 2014). Cannabis legalization is a crucial road safety issue. Since legalizing medical marijuana (2000), Colorado observed increased driving under the influence of cannabis (DUIC) cases (Urfer et al., 2014), and fatal motor vehicle crashes with cannabis-positive drivers; whereas no significant change was observed in 34 states without legalized medical marijuana (Salomonsen-Sautel et al., 2014). Establishing evidence-based *per se* laws for DUIC remains challenging, with varying laws across the US (Armentano, 2013; Grotenhermen et al., 2007; Lacey et al., 2010). Many are concerned

that implementing concentration-based cannabis-driving legislation will unfairly target individuals not acutely intoxicated, because residual THC can be detected in blood for up to a month of sustained abstinence in chronic frequent smokers (Bergamaschi et al., 2013). Appropriate blood THC concentrations that universally reflect driving impairment remain elusive. Determining blood THC concentrations associated with lateral control impairment in occasional users would benefit forensic interpretation.

There is interest in linking driving impairment with oral fluid (OF) THC concentrations. OF is easy to collect, non-invasive, and associated with recent cannabis intake (Bosker and Huestis, 2009; Drummer, 2006; Wille et al., 2014). OF-based DUIC legislation exists in some jurisdictions (Drummer et al., 2007; Huestis et al., 2011; Van der Linden et al., 2012); however, limited simultaneous driving and OF concentration data preclude direct association with impairment.

Alcohol is the most common drug identified in drivers (Berning et al., 2015; Legrand et al., 2013). Cannabis and alcohol, frequently detected together (Legrand et al., 2013), produced greater impairing effects together than either separately (Robbe, 1998; Ronen et al., 2010), but it is unclear whether effects are additive or synergistic.

This is the first in a series of manuscripts evaluating cannabis' effects, with and without concurrent alcohol, on driving. We present here effects, relative to THC concentrations, on drivers' lateral control. We hypothesized cannabis and alcohol would each impair lateral control, with synergistic effects when combined.

2. Methods

2.1 Participants

Healthy adults provided written informed consent for this Institutional Review Board-approved study. Inclusion criteria were ages 21-55years; self-reported cannabis consumption ≥1x/3months but ≤3days/week over the past 3months (Cannabis Use Disorders Identification Test [CUDIT] (Adamson and Sellman, 2003)); self-reported "light" or "moderate" alcohol consumption according to a Quantity-Frequency-Variability (QFV) scale (Sobell and Sobell, 2003); or, if "heavy", not more than 3-4 servings on a typical drinking occasion; licensed driver for ≥2years with currently valid unrestricted license; and self-reported driving ≥1300miles in the past year. Exclusion criteria included past or current clinically significant medical illness; history of clinically significant adverse event associated with cannabis or alcohol intoxication or motion sickness; ≥450mL blood donation in 2weeks preceding drug administration; pregnant/nursing; interest in drug abuse treatment within past 60days; currently taking drugs contraindicated with cannabis or alcohol or known to impact driving; requirements for nonstandard driving equipment; and prior participation in a similar driving simulator study.

2.2 Study Design/Procedures

Participants entered the clinical research unit 10-16h prior to drug administration to preclude acute intoxication. Participants drank 90% grain alcohol in fruit juice to reach approximately 0.065% peak breath alcohol concentration [BrAC], or placebo (juice with alcohol-swabbed rim and topped with 1mL alcohol to mimic alcohol taste and odor) *ad libitum* over 10min. After drinking, they inhaled 500mg placebo (0.008±0.002% THC), low (2.9±0.14%)-, or

high (6.7±0.05%)-THC vaporized (Volcano® Medic, Storz & Bickel, Tuttlingen, Germany) cannabis (NIDA Chemistry and Physiological Systems Research Branch) *ad libitum* over 10min. Participants received all six alcohol/cannabis combinations in randomized order, with sessions separated by ≥1week.

Simulated drives occurred 0.5-1.3h after start of cannabis dosing. Blood collection times were 0.17, 0.42, 1.4, and 2.3h post-inhalation. Blood was collected via indwelling peripheral venous catheter into grey-top (potassium oxalate/sodium fluoride) Vacutainer® tubes (Becton, Dickinson and Company, Franklin Lakes, NJ), and stored on ice ≤2h. Specimens were stored in 3.6mL Nunc® cryotubes (Thomas Scientific, Swedesboro, NJ) at -20°C, and analyzed within 3months, based on known cannabinoid stability (Scheidweiler et al., 2013). OF was collected simultaneously with blood (except 0.42h), with the Quantisal™ collection device (Immunalysis, Pomona, CA). BrAC was measured via Alco-Sensor® IV (Intoximeters, St. Louis, MO) at the same times as blood, reporting alcohol in g/210L breath (limit of quantification [LOQ] 0.006g/210L), equivalent to approximate blood alcohol concentration (BAC).

2.3 National Advanced Driving Simulator

Driving simulations were conducted in NADS-1, the high-fidelity, full-motion simulator at the National Advanced Driving Simulator (NADS), Iowa City, IA (Figure 1). A 1996 Malibu sedan is mounted in a 7.3m-diameter dome with a motion system providing 400m^2 acceleration space, ±330° rotation, and high-frequency motion (Lee et al., 2010). Drivers experience acceleration, braking, steering cues, road conditions (e.g., gravel), and realistic sounds (e.g.,

92 wind, motor). NADS-1 produces a complete record of vehicle state (e.g., lane position) and
93 driver inputs (e.g., steering wheel position).
94
95 2.4 Drives
96
97 The 45min drive challenged multiple driving skills affected by cannabis, including
98 SDLP. Each drive had urban, interstate and rural nighttime segments. The urban segment
99 involved a two-lane city roadway with posted speed limits 25-45miles/h (40-72km/h) and signal-
100 controlled and uncontrolled intersections; interstate, a four-lane divided expressway with posted
101 70miles/h (113km/h) speed limit; rural, two-lane undivided road with curves, a gravel portion,
102 and a 10min timed straightaway. Because each participant drove six times, three scenarios with
103 varied event orders were utilized to minimize practice effects. Each scenario contained the same
104 number of curves and turns, in varied order and position. Other traffic, pedestrians, and potential
105 hazards were present throughout the drive. Hundreds of performance variables were monitored;
106 the lateral control (necessary for road tracking, lane keeping) subset is presented here.
107
108 2.5 Specimen Analysis
109
110 Blood THC concentration was quantified by a previously-published method (Schwope et
111 al., 2011). Briefly, 0.5mL blood was protein-precipitated with ice-cold acetonitrile, and
112 supernatants diluted and solid-phase extracted. THC's linear range was 1-100µg/L. Inter-assay
113 (n=30) analytical bias and imprecision were ≤3.7% and ≤8.7%, respectively. OF THC
114 quantification is described in detail elsewhere (Hartman et al., 2015a). We utilized a published

validated method (Milman et al., 2010), modified by adding 0.4mL hexane to solid-phase extraction columns before the initial elution solvent. THC's linear range was 0.5-50µg/L. Inter- and intra-assay imprecision were ≤6.6%; analytical bias, ≤14.4% (n=21). If concentrations exceeded the upper LOQ, OF specimens were diluted with drug-free Quantisal™ buffer to achieve concentrations within the method's linear range.

2.6 Data Analysis

Blood THC concentrations during drives were modeled via individual power-curve regression from pre-drive (0.17 and 0.42h) and post-drive (1.4 and 2.3h) specimens. BrAC concentrations during drives were modeled by linear interpolation, as alcohol was in the post-absorptive phase, during which its pharmacokinetics are linear (Jones and Andersson, 2003). Driving data were analyzed by participants' modeled concentrations during drives.

Data were reviewed to determine which events were suitable for analysis. Events for which dependent measures were not meaningful (e.g., SDLP during turn), were excluded. For each dependent measure, events with similar means were grouped for analytic purposes. Data were analyzed using SAS v9.4 General Linear Model (GLM) Select function to identify appropriate regression models. This procedure was selected due to its ability to accommodate continuous dependent measures and combinations of continuous and categorical independent measures (Neerchal et al., 2014). The stepwise selection method was chosen; the Schwarz Bayesian Information Criterion determined model entry/removal (Schwarz, 1978). Effect hierarchy was not enforced on model parameters. Available model parameters were blood THC, BrAC, interaction term THC*BrAC, speed limit, inverse curvature, and subject. Dependent

138 measures of drivers' lateral control included SDLP, standard deviation of steering wheel angle,
139 lane departures/min ("lane departure" defined as edge of vehicle crossing a lane boundary; per
140 minute allowed for normalization across drive events), and maximum lateral acceleration in
141 events without sharp turns. For final regression models, the analysis of variance for the model fit
142 is presented, along with estimates, t-values, and p-values for model parameters.
143
144 *3. Results*
145
146 3.1 Participants
147
148 Nineteen healthy adults (13 men, ages 21-37 years, 74% white) participated (Table 1).
149 Most consumed cannabis ≥2x/month (but ≤3days/week), and reported last intake within a week
150 prior to admission. Participants self-reported driving 6-23 years, and all reported driving
151 ≥1x/week. Data review revealed one participant (#12) was consistently an extreme outlier in
152 almost all measures and dosing conditions, including placebo cannabis/placebo alcohol. Driving
153 videos indicated markedly erratic and abnormal driving behavior, inattention, and distractibility
154 in all conditions, suggesting invalid data. These data were excluded from all driving analyses,
155 yielding N=18 completing drivers.
156
157 3.2 Driving
158
159 GLM Select model results are depicted in Table 2. THC concentration and BrAC
160 significantly associated with SDLP, but the interaction (THC*BrAC) was not selected into the

model. This indicates additive, rather than synergistic, cannabis and alcohol effects. To account for a possible ceiling effect of increasing concentrations, quadratic terms THC^2 and $BrAC^2$ were added to the list of potential predictors; neither was included in the resultant model. The model predicts that blood THC and BrAC increased SDLP 0.26 cm per µg/L THC and 0.42 cm per 0.01g/210L BrAC (Table 3), representing 0.8% and 1.3% increases relative to median baseline (drug-free) SDLP per µg/L THC or 0.01g/210L BrAC, respectively. Participants displayed high inter-individual variability in baseline (drug-free) SDLP (Supplemental Figure 1). BrAC concentrations of 0.05% and 0.08%, the most common *per se* alcohol limits worldwide, were associated with similar SDLP to 8.2 and 13.1µg/L THC concentrations, respectively (Figure 2). Low (1 and 2µg/L) blood THC concentrations were associated with SDLP increases similar to 0.01g/210L BrAC. At 5µg/L THC, a 4.1% increase in SDLP was observed; at 10µg/L, SDLP increased 8.2%. This change was comparable to 0.05g/210L BrAC (6.7% increase) and 0.08g/210L BrAC (11% increase).

Natural-log SDLP transformation is common analytical practice due to non-normal distribution. Results obtained from ln(SDLP) (Supplemental Tables 1 and 2) were similar to untransformed SDLP; therefore, we report the more straightforward and conservative SDLP results.

BrAC significantly increased lane departures/min and maximum lateral acceleration; these measures were not sensitive to cannabis. Neither THC nor BrAC affected standard deviation of steering wheel angle.

THC concentration-based statistical analysis was utilized because of substantial overlap in achieved THC blood C_{max} across the active-THC dose groups (Figure 3): 6 participants achieved higher C_{max} after the low than high-THC dose and 4 had low and high C_{max} within 20%

of one another despite a 2-fold dose difference. This overlap makes statistical analysis by dose group (Table 4) not scientifically meaningful, illustrating the importance of analyzing effects by actual blood THC. THC concentration peaks prior to finishing inhalation (Huestis et al., 1992), and inhalation variability causes THC concentration variability (Azorlosa et al., 1995, Hartman et al., 2015b). Table 5 presents mean (SD) results by THC and alcohol condition.

3.3 Pre- and Post-drive Blood and OF THC Concentrations

Table 6 presents pre- and post-drive blood and OF concentrations. Full blood and OF pharmacokinetic data are presented in (Hartman et al., 2015b) and (Hartman et al., 2015a), respectively. Between-subject blood concentration variability (coefficient of variation) was substantially lower than matched OF concentration variability at all time points: 45-65% vs. 125-207%, respectively, immediately post-dose; 39-69% vs. 129-184% at 1.4h; and 61-82% vs. 139-174% at 2.3h (Table 6).

4. Discussion

Using a sophisticated driving simulator and rigorous placebo-controlled, within-subject design, we found a positive association between blood THC concentration and one (SDLP) of 3 alcohol-sensitive lateral control impairment measures (SDLP, normalized lane departures, maximum acceleration). Cannabis-alcohol combination effects were additive, not synergistic.

Decreased lateral control was associated with blood THC concentrations and BrAC, based on descriptive models. SDLP is among the most sensitive and consistently utilized driving

impairment measures (Charlton and Starkey, 2013; Ramaekers et al., 2006a; Verster and Roth, 2011, 2012). Given that most countries have 0.05 or 0.08% BAC *per se* laws, the observed SDLP increase may be substantial enough to be considered impairment. Although SDLP (experimental measure) is not directly validated to predict crash risk (epidemiological measure), it is an objective measure of continuous behavior while driving (Lococo and Staplin, 2006). The lowest criterion of drug-induced driving impairment is considered to be SDLP consistent with 0.05 BAC, approximately 2.4cm (Lococo and Staplin, 2006). In this study, ≥8.2µg/L THC met that criterion. The increase associated with 10µg/L THC also was similar to 2µg/L THC+0.05g/210L BrAC (8.4% increase). At higher 20µg/L THC, SDLP increased 16%, comparable to 0.10g/210L BrAC (13% increase). In an on-road study (Ramaekers et al., 2000; Robbe, 1998), 100, 200 and 300µg/kg THC doses (~7mg, ~14mg, ~21mg) significantly increased SDLP 1.7-3.5cm relative to placebo. These increases are consistent with our 7-10µg/L during-drive THC (5.8-8.2% increase) or 0.05-0.08g/210L BrAC (6.7-10.7% increase, Table 3). Our final lane departures/min and maximum lateral acceleration GLM Select models did not include THC, indicating increasing THC concentrations did not increase these measures. Alcohol concentration-dependently increased lane departures/min and maximum lateral acceleration, with 0.05g/210L corresponding to 35% and 9.5% increases, respectively.

Combining cannabis with alcohol produced an additive—rather than synergistic—effect on SDLP, with no interaction term. Past simulator studies were inconsistent regarding SDLP cannabis-alcohol interactions. Ronen et al (2010) observed significant increases in lane position variability when 13mg THC and 0.05% (BAC) alcohol were combined, despite neither producing an independent significant effect. Conversely, Lenné et al (2010) observed significant main effects of cannabis and alcohol independently, but no interaction (combined effects not

synergistic), similar to our findings. Combining 100 or 200μg/kg THC with 0.04% target BAC in the on-road study described above significantly increased SDLP by 5.3 and 8.5cm, classified as "severe" performance decrements (Ramaekers et al., 2000; Robbe, 1998). In our model, this increase is similar to ≥20μg/L blood THC alone. Although epidemiological studies do not quantify crash risk by SDLP, increases in lane weave may lead to more lane departures (detected by Downey et al., 2013) and, in turn, more crashes. Cannabis approximately doubled crash risk in two recent epidemiological meta-analyses (Li et al., 2012; Asbridge et al., 2012).

Unlike cannabis, alcohol affected additional lateral control parameters besides SDLP. Lane departures/min and maximum lateral acceleration also increased with BrAC, consistent with prior NADS alcohol findings (Lee et al., 2010). This suggests more extreme reaction to lateral position when DUI alcohol, compared to DUIC. Cannabis-influenced drivers may attempt to drive more cautiously to compensate for impairing effects, whereas alcohol-influenced drivers often underestimate their impairment and take more risks (Sewell et al., 2009). Alcohol's strong effects on driving are well-established (Charlton and Starkey, 2013; Charlton and Starkey, 2015; Moskowitz and Fiorentino, 2000; Van Dyke and Fillmore, 2014). Alcohol increased center and edge lane crossings, and time over the edge line in a simulated drive (Charlton and Starkey, 2013). Lack of observed cannabis effects on lane departures contrasts with prior findings. Downey et al. (2013) observed dose-dependent cannabis effects on straddling lane barrier or solid lines, with or without alcohol, in simulated nighttime driving. That study had more participants (80), possibly providing higher power to detect weak effects. In one on-road study, only cannabis-alcohol combinations significantly increased time out of lane (Ramaekers et al., 2000; Robbe, 1998); neither cannabis nor alcohol (0.04% BAC) alone produced a significant effect. Because increasing lane departures and "time out of lane" require more substantial lane

weaving than SDLP, this discrepancy may result from the low alcohol dose administered in that study. SDLP is more sensitive, with observable impairment at BACs as low as 0.04% (Moskowitz and Fiorentino, 2000).

Neither cannabis nor alcohol affected standard deviation of steering angle. To our knowledge, only one prior simulator study found a significant alcohol effect on this parameter: 0.6g/kg alcohol (peak BACs ~0.05%) produced a significant but small increase in standard deviation of steering angle (Lenné et al., 2010). Lower 0.4g/kg (peak BACs ≤0.025%) had no effect. Although cannabis alone (19, 38mg) did not significantly increase steering angle variability (main effect), there was significant interaction with driver experience. Experienced drivers (≥7 years driving) showed unchanged or decreased steering angle variability with increasing cannabis dose relative to placebo; inexperienced drivers (<2 years) had increased variability (Lenné et al., 2010). All of our participants had ≥6 years of driving experience, perhaps accounting for this discrepancy. Lenné et al. (2010) also analyzed effects by dose rather than concentration, possibly resulting in greater apparent effect size because dose-wise (categorical) variable analyses generally have higher power than continuous variables. Multiple other studies found no cannabis-only effect on steering wheel position variability (Anderson et al., 2010; Ronen et al., 2010), although one observed increased steering variability in occasional smokers after alcohol alone and alcohol-cannabis combination (Ronen et al., 2010). Standard deviation of steering angle appears insensitive, due to the amplifying effect of steering mechanisms. Minor steering adjustments can substantially alter course and change lane position due to forward motion, despite re-straightening the wheel.

By controlling *ad libitum* inhalation topography (e.g., inhalation rate, depth, hold time), smokers can self-titrate cannabis dose to achieve desired pharmacological response *(*Azorlosa et

al., 1995). We infer self-titration from the observed disjunction between dose and THC concentration; there is often poor correlation between THC dose and blood concentration, making concentration-based analysis more meaningful and robust than dose-based analysis (see Tables 4-5, Figure 3). In our sample, 52.6% of participants showed evidence of self-titration (Hartman et al 2015b). Substantial concentration variability was observed, consistent with prior cannabis research (Desrosiers et al., 2014). This further underscores the robustness of concentration-based—rather than dose-based— analysis.

There is substantial interest in relating driving performance directly to OF concentrations due to screening advantages. THC enters OF primarily by oromucosal contamination during inhalation, and consequently is less representative of systemic concentrations shortly after intake. OF concentration variability was 2-5-fold higher than for paired blood concentrations, making interpretation of effects more challenging. Similar to blood, low OF THC concentrations are difficult to interpret because intake history and individual variability affect detection time and later concentrations. However, in this sample, OF THC >1600µg/L indicated intake within the last 1.4h, and >600µg/L indicated intake within the last 2.3h. In a roadside study, the percentage of people displaying observable cannabis-related impairment increased with increasing OF concentrations when aggregated into wide ranges (≤3µg/L, 3-25µg/L, 25-100µg/L, >100µg/L) (Fierro et al., 2014).

4.1 Strengths and limitations

Major study strengths include the double-blind, placebo-controlled, within-subject design; drive scenarios controlling for other road conditions (speed limit and curvature), which

potentially affect drivers' lateral control and road tracking performance; administration of multiple doses of cannabis (THC) with/without alcohol; concentration-based analysis; and multiple specimen collections before and after driving (allowing during-drive pharmacokinetic modeling), to better relate driving impairment to THC concentrations.

In authentic DUIC cases, measured THC concentrations do not reflect those present during driving. Blood collection is typically delayed 90min to 4h after the event (Biecheler et al., 2008; Jones et al., 2008). During this delay, there is rapid THC distribution from blood into highly-perfused tissues, resulting in rapid blood THC concentration decrease in the first hour post-inhalation. Later, THC concentration continues to decrease, albeit more slowly. This results in lower measured THC concentrations than were present during driving. In contrast, we examined driving performance relative to THC concentrations and BrAC that were present *during* driving. Thus, to our knowledge, the current study is among the most robust analyses of cannabis and alcohol effects on lateral control at specific THC concentrations. For context, we report driving performance results at concentrations typically considered or established for *per se* laws around the world (1, 2, 5, 7µg/L THC; 0.02, 0.05, 0.08% BrAC) (Armentano, 2013; Grotenhermen et al., 2007; Karakus et al., 2014; Lacey et al., 2010; Ramaekers et al., 2006b; Verstraete A, 2011). However, these *per se* limits are applied to THC concentrations that may substantially underestimate concentrations during driving. Thus, our reported THC 1-5µg/L SDLP changes may be understated compared to forensic DUIC cases. In the present study, median blood and OF THC concentrations immediately post-dose were >30µg/L and >700µg/L, respectively. Blood THC ≥20µg/L indicated intake within the last 0.42h and THC ≥10µg/L indicated intake within the last 1.4h. Thus, if people drive during or soon after cannabis inhalation, during-drive THC concentrations could exceed 20µg/L. Our SDLP increase

associated with THC ≥20µg/L (~5.2cm) was considered "severe" by other researchers (Ramaekers et al., 2000; Robbe, 1998), representing a 16% increase in our observed lane position variability. Despite lack of significant THC effect on lane departures/min, our results suggest substantial lateral control performance decrements, consistent with effects produced by known impairing alcohol concentrations. Verster and Roth (2014) determined that lane departures alone were not sufficiently sensitive to experimentally detect impaired driving or effect size differences. SDLP is a sensitive marker, serving as experimental proxy for rarer events such as lane departures. Even minor lateral control decrements may be dangerous in narrow or winding roads, or in heavy traffic where navigational precision or defensive driving may be required.

This study has several limitations. We approached data analyses via a stepwise GLM Select procedure, with the goal of describing data without assumptions of which parameters (THC, BrAC, other) would produce fixed effects. In research settings, participants are aware driving is constantly under observation, and may drive with greater caution or focus. Other participants may have wanted to demonstrate that cannabis does not affect driving; public attitudes toward DUIC are less negative than for DUI alcohol (McCarthy et al., 2007; Terry and Wright, 2005). However, self-perception of driving performance or impairment—even without drugs—may be unreliable (Van Dyke and Fillmore 2014; Verster and Roth, 2012).

This study was limited to occasional smokers. Frequent cannabis smokers demonstrate tolerance to some acute cannabis intoxication effects (Ramaekers et al., 2011), but tolerance did not compensate for all effects (Downey et al., 2013). There is currently substantial interest in comparing occasional to frequent smokers and assessing potential tolerance (Ramaekers et al.,

2009; Toennes SW et al., 2008; Wright and Terry, 2002), especially as medical and recreational cannabis becomes more commonplace.

We do not believe that conducting this study in a driving simulator, rather than on the road, represents a significant limitation. Rather, simulators offer advantages for assessing impaired driving. Participants can engage in risky driving behavior without endangering themselves or others. Simulators provide controlled reproducible research environments and ability to make detailed real-time measurements. Modern simulators produce highly realistic driving scenarios (Hartman and Huestis, 2012). The NADS-1 is the world's most sophisticated simulator, and was successfully utilized to assess distracted and drugged driving (Garrott et al., 2005; Lee et al., 2010).

5. Conclusion

In this rigorous, double-blind, placebo-controlled study, cannabis and alcohol were significantly associated with impaired driving lateral control. Cannabis only affected SDLP; whereas alcohol affected SDLP, lane departures/min, and maximum acceleration. During-drive 8.2µg/L blood THC was associated with SDLP increases similar to 0.05g/210L BrAC (~0.05% BAC), and SDLP at 13.1µg/L THC approximated 0.08g/210L BrAC. Combining alcohol and cannabis produced an additive effect on SDLP; 5µg/L THC with 0.05g/210L BrAC was similar to 0.08g/210L SDLP impairment. These THC concentrations during driving are higher than those generally measured hours later during sample collection. OF concentration variability was substantially greater than blood concentration variability, suggesting better performance as a screening tool than impairment gauge.

References

Adamson, S.J., Sellman, J.D., 2003. A prototype screening instrument for cannabis use disorder: the Cannabis Use Disorders Identification Test (CUDIT) in an alcohol-dependent clinical sample. Drug Alcohol Rev. 22, 309-315.

Anderson, B.M., Rizzo, M., Block, R.I., Pearlson, G.D., O'Leary, D.S., 2010. Sex differences in the effects of marijuana on simulated driving performance. J. Psychoactive Drugs 42, 19-30.

Armentano, P., 2013. Should Per Se Limits Be Imposed For Cannabis? Equating Cannabinoid Blood Concentrations with Actual Driver Impairment: Practical Limitations and Concerns. Humboldt J. Social Relations, 45-55.

Asbridge, M., Hayden, J.A., Cartwright, J.L., 2012. Acute cannabis consumption and motor vehicle collision risk: Systematic review of observational studies and meta-analysis. BMJ 344, e536.

Azorlosa, J.L., Greenwald, M.K., Stitzer, M.L., 1995. Marijuana smoking: Effects of varying puff volume and breathhold duration. J. Pharmacol. Exp. Ther. 272, 560-569.

Bergamaschi, M.M., Karschner, E.L., Goodwin, R.S., Scheidweiler, K.B., Hirvonen, J., Queiroz, R.H., Huestis, M.A., 2013. Impact of prolonged cannabinoid excretion in chronic daily cannabis smokers' blood on per se drugged driving laws. Clin. Chem. 59, 519-526.

Berning, A., Compton, R., Wochinger, K., 2015. Results of the 2013-2014 National Roadside Survey of Alcohol and Drug Use by Drivers. Traffic Safety Facts: Research Note. National Highway Traffic Safety Administration, US Department of Transportation, Washington, DC. Report No. DOT HS 812 118.

Biecheler, M.B., Peytavin, J.F., Facy, F., Martineau, H., 2008. SAM survey on "Drugs and fatal accidents": search of substances consumed and comparison between drivers involved under the influence of alcohol or cannabis. Traffic. Inj. Prev. 9, 11-21.

Bosker, W.M., Huestis, M.A., 2009. Oral Fluid Testing for Drugs of Abuse. Clin. Chem. 55, 1910-1931.

Charlton, S.G., Starkey, N.J., 2013. Driver risk from blood alcohol levels between 50mg/100ml and 80mg/100ml. NZ Transport Agency Research Report Traffic and Road Safety Research Group,University of WaikatO, Hamilton, NZ. Doc. No. 541.

Charlton, S.G., Starkey, N.J., 2015. Driving while drinking: performance impairments resulting from social drinking. Accid. Anal. Prev. 74, 210-217.

Desrosiers, N.A., Himes, S.K., Scheidweiler, K.B., Concheiro-Guisan, M., Gorelick, D.A., Huestis, M.A., 2014. Phase I and II Cannabinoid Disposition in Blood and Plasma of Occasional and Frequent Smokers Following Controlled Smoked Cannabis. Clin. Chem. 60, 631-643.

Downey, L.A., King, R., Papafotiou, K., Swann, P., Ogden, E., Boorman, M., Stough, C., 2013. The effects of cannabis and alcohol on simulated driving: Influences of dose and experience. Accid Anal. Prev. 50, 879-886.

Drummer, O.H., 2006. Drug testing in oral fluid. Clin. Biochem. Rev. 27, 147-159.

Drummer, O.H., Gerostamoulos, D., Chu, M., Swann, P., Boorman, M., Cairns, I., 2007. Drugs in oral fluid in randomly selected drivers. Forensic Sci. Int. 170, 105-110.

Drummer, O.H., Gerostamoulos, J., Batziris, H., Chu, M., Caplehorn, J., Robertson, M.D., Swann, P., 2004. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accident Anal. Prev. 36, 239-248.

Fierro, I., Gonzalez-Luque, J.C., Alvarez, F.J., 2014. The relationship between observed signs of impairment and THC concentration in oral fluid. Drug Alcohol Depend. 144, 231-238.
Garrott, W.R., Mazzae, E.N., Goodman, M.J., 2005. NHTSA's National Advanced Driving Simulator Research Program. National Highway Traffic Safety Administration. Paper No. 05-0377.
Gjerde, H., Normann, P.T., Christophersen, A.S., Samuelsen, S.O., Mørland, J., 2011. Alcohol, psychoactive drugs and fatal road traffic accidents in Norway: A case-control study. Accident Anal. Prev. 43, 1197-1203.
Grotenhermen, F., Leson, G., Berghaus, G., Drummer, O.H., Krüger, H.P., Longo, M., Moskowitz, H., Perrine, B., Ramaekers, J.G., Smiley, A., Tunbridge, R., 2007. Developing limits for driving under cannabis. Addiction 102, 1910-1917.
Hartman, R.L., Anizan, S., Jang, M., Brown, T.L., Yun, K., Gorelick, D.A., Milavetz, G., Spurgin, A., Gaffney, G., Huestis, M.A., 2015a. Cannabinoid disposition in oral fluid after controlled vaporizer administration with and without alcohol Forensic Toxicol. Doi: 10.1007/s11419-015-0269-6
Hartman, R.L., Brown, T.L., Milavetz, G., Spurgin, A., Gorelick, D.A., Gaffney, G., Huestis, M.A., 2015b. Controlled Cannabis Vaporizer Administration: Blood and Plasma Cannabinoids With and Without Alcohol. Clin. Chem. 61, 850-69.
Hartman, R.L., Huestis, M.A., 2013. Cannabis Effects on Driving Skills. Clin Chem. 59, 478-492.
Huestis, M.A., Henningfield, J.E., Cone, E.J., 1992. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J. Anal. Toxicol. 16, 276-82.
Huestis, M.A., Verstraete, A., Kwong, T.C., Morland, J., Vincent, M.J., De La Torre, R., 2011. Oral fluid testing: Promises and pitfalls. Clin. Chem. 57, 805-810.
Jones, A.W., Andersson, L., 2003. Comparison of ethanol concentrations in venous blood and end-expired breath during a controlled drinking study. Forensic Sci. Int. 132, 18-25.
Jones, A.W., Holmgren, A., Kugelberg, F.C., 2008. Driving under the influence of cannabis: a 10-year study of age and gender differences in the concentrations of tetrahydrocannabinol in blood. Addiction 103, 452-461.
Karakus, A., Idiz, N., Dalgic, M., Ulucay, T., Sincar, Y., 2014. Comparison of the Effects of Two Legal Blood Alcohol Limits: The Presence of Alcohol in Traffic Accidents According to Category of Driver in Izmir, Turkey. Traffic Inj. Prev. Doi: 10.1080/15389588.2014.968777
Lacey, J., Brainard, K., Snitow, S., 2010. Drug Per Se Laws: A Review of Their Use in States. National Highway Traffic Safety Administration. Report No. DOT HS 811 317.
Lacey, J.H., Kelley-Baker, T., Furr-Holden, D., Voas, R.B., Romano, E., Ramirez, A., Brainard, K., Moore, C., Torres, P., Berning, A., 2009. 2007 National Roadside Survey of Alcohol and Drug Use by Drivers: Drug Results. National Highway Traffic Safety Administration Office of Behavioral Safety Research. Report No. DOT HS 811 249.
Laumon, B., Gadegbeku, B., Martin, J.-L., Biecheler, M.-B., 2005. Cannabis intoxication and fatal road crashes in France: population based case-control study. BMJ 331, 1371.
Lee, J.D., Fiorentino, D., Reyes, M.L., Brown, T.L., Ahmad, O., Fell, J., Ward, N., Dufour, R., 2010. Assessing the Feasibility of Vehicle-Based Sensors to Detect Alcohol Impairment. National Highway Traffic Safety Administration. Report No. DOT HS 811 358.

Legrand, S.A., Isalberti, C., der Linden, T.V., Bernhoft, I.M., Hels, T., Simonsen, K.W., Favretto, D., Ferrara, S.D., Caplinskiene, M., Minkuviene, Z., Pauliukevicius, A., Houwing, S., Mathijssen, R., Lillsunde, P., Langel, K., Blencowe, T., Verstraete, A.G., 2013. Alcohol and drugs in seriously injured drivers in six European countries. Drug Test. Anal. 5, 156-165.

Lenné, M.G., Dietze, P.M., Triggs, T.J., Walmsley, S., Murphy, B., Redman, J.R., 2010. The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand. Accident Anal. Prev. 42, 859-866.

Li, M.C., Brady, J.E., DiMaggio, C.J., Lusardi, A.R., Tzong, K.Y., Li, G., 2012. Marijuana use and motor vehicle crashes. Epidemiol. Rev. 34, 65-72.

Lococo, K.H., Staplin, L., 2006. Literature review of polypharmacy and older drivers: Identifying strategies to collect drug usage and driving functioning among older drivers. National Highway Traffic Safety Administration, US Department of Transportation, Washington, DC. Report No. DOT HS 810 558.

McCarthy, D.M., Lynch, A.M., Pederson, S.L., 2007. Driving after use of alcohol and marijuana in college students. Psychol. Addict. Behav. 21, 425-430.

Milman, G., Barnes, A.J., Lowe, R.H., Huestis, M.A., 2010. Simultaneous quantification of cannabinoids and metabolites in oral fluid by two-dimensional gas chromatography mass spectrometry. J. Chrom. A 1217, 1513–1521.

Moskowitz, H., Fiorentino, D., 2000. A review of the literature on the effects of low doses of alcohol on driving-related skills. National Highway Traffic Safety Administration. Report No. DOT HS 809 028.

Neerchal, N.K., Morel, J.G., Huang, X., Moluh, A., 2014. A Stepwise Algorithm for Generalized Linear Mixed Models. SAS Global Forum, Washington, DC. pp. 1822-2014.

O.N.D.C.P., 2013. Office of National Drug Control Policy. White House, Washington, DC. http://www.whitehouse.gov/ondcp. Accessed on 7 August 2013.

Pilkinton, M.W., Robertson, A., McCluskey, D.L., 2013. Drugged driving: increased traffic risks involving licit and illicit substances. J. Drug Educ. 43, 183-201.

ProCon.org, 2014. 23 Legal Medical Marijuana States and DC: Laws, Fees, and Possession Limits. http://medicalmarijuana.procon.org/view.resource.php?resourceID=000881. Accessed on 2 Dec 2014.

Ramaekers, J., Kauert, G., Theunissen, E., Toennes, S., Moeller, M., 2009. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. J. Psychopharmacol. 23, 266-277.

Ramaekers, J., Theunissen, E., de Brouwer, M., Toennes, S., Moeller, M., Kauert, G., 2011. Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. Psychopharmacology 214, 391-401.

Ramaekers, J.G., Kuypers, K.P., Samyn, N., 2006a. Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 mg and methylphenidate 20 mg on actual driving during intoxication and withdrawal. Addiction 101, 1614-1621.

Ramaekers, J.G., Moeller, M.R., van Ruitenbeek, P., Theunissen, E.L., Schneider, E., Kauert, G., 2006b. Cognition and motor control as a function of Δ9-THC concentration in serum and oral fluid: Limits of impairment. Drug Alcohol Depend. 85, 114-122.

Ramaekers, J.G., Robbe, H.W.J., O'Hanlon, J.F., 2000. Marijuana, alcohol and actual driving performance. Hum. Psychopharm. 15, 551-558.

503 Robbe, H., 1998. Marijuana's impairing effects on driving are moderate when taken alone but
504 severe when combined with alcohol. Hum. Psychopharm. 13, S70-S78.
505 Ronen, A., Chassidim, H.S., Gershon, P., Parmet, Y., Rabinovich, A., Bar-Hamburger, R.,
506 Cassuto, Y., Shinar, D., 2010. The effect of alcohol, THC and their combination on
507 perceived effects, willingness to drive and performance of driving and non-driving tasks.
508 Accident Anal. Prev. 42, 1855-1865.
509 Salomonsen-Sautel, S., Min, S.J., Sakai, J.T., Thurstone, C., Hopfer, C., 2014. Trends in fatal
510 motor vehicle crashes before and after marijuana commercialization in Colorado. Drug
511 Alcohol Depend. 140, 137-144.
512 Scheidweiler, K.B., Schwope, D.M., Karschner, E.L., Desrosiers, N.A., Gorelick, D.A., Huestis,
513 M.A., 2013. In Vitro Stability of Free and Glucuronidated Cannabinoids in Blood and
514 Plasma Following Controlled Smoked Cannabis. Clin. Chem. 59, 1108-1117.
515 Schwarz, G., 1978. Estimating the Dimension of a Model. The Annals of Statistics 6, 461-464.
516 Schwope, D., Scheidweiler, K., Huestis, M., 2011. Direct quantification of cannabinoids and
517 cannabinoid glucuronides in whole blood by liquid chromatography–tandem mass
518 spectrometry. Anal. Bioanal. Chem. 401, 1273-1283.
519 Sewell, R.A., Poling, J., Sofuoglu, M., 2009. The effect of cannabis compared with alcohol on
520 driving. Am. J. Addict. 18, 185-193.
521 Sobell, L.C., Sobell, M.B., 2003. Alcohol Consumption Measures. in: Allen, J.P., Wilson, V.B.
522 (Eds.), Assessing Alcohol Problems: A Guide for Clinicians and Researchers. National
523 Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD.
524 pp. 75-99.
525 Terry, P., Wright, K.A., 2005. Self-reported driving behaviour and attitudes towards driving
526 under the influence of cannabis among three different user groups in England. Addict.
527 Behav. 30, 619-626.
528 Toennes SW, Ramaekers JG, Theunissen EL, Moeller MR, Kauert GF, 2008. Comparison of
529 Cannabinoid Pharmacokinetic Properties in Occasional and Heavy Users Smoking a
530 Marijuana or Placebo Joint. J. Anal. Toxicol. 32, 470-477.
531 Urfer, S., Morton, J., Beall, V., Feldmann, J., Gunesch, J., 2014. Analysis of Delta9-
532 tetrahydrocannabinol driving under the influence of drugs cases in Colorado from January
533 2011 to February 2014. J. Anal. Toxicol. 38, 575-581.
534 Van der Linden, T., Legrand, S.A., Silverans, P., Verstraete, A.G., 2012. DUID: oral fluid and
535 blood confirmation compared in Belgium. J. Anal. Toxicol. 36, 418-421.
536 Van Dyke, N., Fillmore, M.T., 2014. Alcohol effects on simulated driving performance and self-
537 perceptions of impairment in DUI offenders. Exp. Clin. Psychopharmacol. 22, 484-493.
538 Verster, J.C., Roth, T., 2011. Standard operation procedures for conducting the on-the-road
539 driving test, and measurement of the standard deviation of lateral position (SDLP). Int. J.
540 Gen. Med. 4, 359-371.
541 Verster, J.C., Roth, T., 2012. Drivers can poorly predict their own driving impairment: a
542 comparison between measurements of subjective and objective driving quality.
543 Psychopharmacology (Berl) 219, 775-781.
544 Verster, J.C., Roth, T., 2014. Excursions out-of-lane versus standard deviation of lateral position
545 as outcome measure of on-the-road driving test. Hum. Psychopharmacol. Clin. Exp. 29,
546 322-329.

Verster, J.C., Veldhuijzen, D.S., Patat, A., Olivier, B., Volkerts, E.R., 2006. Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr. Drug. Saf. 1, 63-71.

Verstraete A., K.A., Jantos R., Skopp G., Gjerde H., Vindenes V., et al, 2011. Per se limits – Methods of defining cut-off values for zero tolerance. DRUID (Driving under the Influence of Drugs, Alcohol and Medicines). Doc. No. TREN-05-FP6TR-S07.61320-518404-DRUID.

Wille, S.M., Di Fazio, V., Toennes, S.W., van Wel, J.H., Ramaekers, J.G., Samyn, N., 2014. Evaluation of Delta9-tetrahydrocannabinol detection using DrugWipe5S screening and oral fluid quantification after Quantisal collection for roadside drug detection via a controlled study with chronic cannabis users. Drug Test Anal. 7, 178-86. Doi: 10.1002/dta.1660.

Wright, K., Terry, P., 2002. Modulation of the effects of alcohol on driving-related psychomotor skills by chronic exposure to cannabis. Psychopharmacology 160, 213-219.

Table 1. Self-reported demographic characteristics, recent cannabis and alcohol consumption and driving history of 19 healthy adult occasional cannabis smokers

Participant	Sex	Age (years)	Race and ethnicity	BMI (kg/m^2)	Alcohol intake frequency	Typical drinks per occasion	Cannabis intake frequency	Hours "stoned" on typical cannabis occasion[a]	Time since last cannabis consumed (days)	Amount last consumed[b] (joint or joint equivalent)	Years of driving experience	Driving frequency
1	M	23.7	W	24.3	2-3x/wk	2-4	2-4x/m	1-2	1	1	7	≥1x/d
2	F	28.4	AA	23.8	≥4x/wk	2-4	2-4x/m	3-4	14	1	--[c]	--[c]
3	M	21.9	W	24.7	2-3x/wk	5-6	2-4x/m	1-2	6	1	7	≥1x/d
4	M	37.8	W	26.1	2-3x/wk	2-4	2-3x/wk	1-2	3	2.5	23	≥1x/d
5	M	26.6	W	21.6	≤1x/m	2-4	≤1x/m	1-2	11	3.5	12	≥1x/d
6	F	26.3	W	20.0	2-3x/wk	2-4	2-3x/wk	3-4	1	0.25	12	≥1x/d
7	M	25.8	W	40.6	2-4x/m	2-4	2-3x/wk	1-2	0.3	0.5	11	≥1x/d
8	M	26.1	H	31.5	2-4x/m	1-2	2-3x/wk	1-2	3	1	10	≥1x/d
9	M	23.2	W	19.5	2-3x/wk	2-4	2-3x/wk	3-4	2	1	7	≥1x/wk
10	M	23.1	W	23.9	2-4x/m	2-4	≤1x/m	1-2	2	0.25	9	≥1x/d
11	M	32.3	O, H	28.9	2-3x/wk	2-4	2-3x/wk	1-2	4	1	16	≥1x/d
12[d]	F	23.4	W	23.3	2-3x/wk	2-4	2-4x/m	3-4	4	1	8	≥1x/wk
13	F	30.3	AA	24.1	2-3x/wk	2-4	≤1x/m	<1	120	1	14	≥1x/d
14	M	24.6	W	23.3	2-3x/wk	2-4	2-4x/m	1-2	7	0.8	8	≥1x/wk
15	M	21.8	W	32.7	≤1x/m	1-2	2-4x/m	1-2	7	0.13	6	≥1x/d
16	F	21.7	AA, W	23.0	2-4x/m	1-2	2-3x/wk	1-2	1.1	1.5	7	≥1x/d
17	M	28.7	W	18.3	2-3x/wk	2-4	≤1x/m	3-4	45	0.5	12	≥1x/wk
18	M	28.1	W	48.3	2-4x/m	2-4	2-4x/m	3-4	5	1	12	≥1x/d
19	F	22.9	W	21.6	2-4x/m	5-6	2-3x/wk	3-4	1	1	6	≥1x/d
Median (all)		25.8		23.9					4.0	1.0	10	
Mean (all)		26.1		26.3					12.5	1.0	10	
StDev (all)		4.1		7.5					27.9	0.8	4	
Median (N=18)		25.9		24.0					3.5	1.0	10	
Mean (N=18)		26.3		26.5					13.0	1.1	11	
StDev (N=18)		4.2		7.7					28.6	0.8	4	

[a]"Hours "stoned" " wording originates from Cannabis Use Disorders Identification Test, source of self-reported cannabis frequency data

[b]Cannabis amount last consumed is based on empirically-normalized joint consumption, to account for various administration routes and self-reported "sharing" between multiple individuals

[c]Participant did not provide response

[d]Participant excluded from driving analyses due to consistently outlying behavior

Abbreviations: W, White; AA, African American; H, Hispanic or Latino; As, Asian; O, Other; AI, American Indian/Native American; StDev, standard deviation

Table 2. General Linear Model (GLM) Select results of effects on lateral control measures in 18 volunteer drivers after controlled vaporized cannabis with or without oral alcohol.

Parameter	DF	Estimate (b)	t	Standard Error	p-value
Standard Deviation of Lateral Position (SDLP)					
THC	1	0.26	3.6	0.07	0.0004
BrAC	1	0.42	2.9	0.15	0.0037
THC*BrAC					
Speed Limit	1	0.50	19	0.03	<0.0001
Inverse Curvature	1	464	9.5	49	<0.0001
Intercept	1	17.3	8.3	2.1	<0.0001
Subject	17				
Model df:	21				
Model F-value	28.24				
Error df:	1916				
Standard Deviation of Steering Angle (Curvy)					
THC					
BrAC					
THC*BrAC					
Speed Limit	1	0.07	5.4	0.01	<0.0001
Inverse Curvature	1	-122	-7.7	16	<0.0001
Intercept	1	5.2	9.0	0.6	<0.0001
Subject					
Model df:	2				
Model F-value	29.59				
Error df:	427				
Standard Deviation of Steering Angle (Straight)					
THC					
BrAC					
THC*BrAC					
Speed Limit	1	-0.40	-17	0.02	<0.0001
Inverse Curvature	1	1389	27	51	<0.0001
Intercept	1	25	21	1.2	<0.0001
Subject					
Model df:	2				
Model F-value	657.9				
Error df:	1936				
Lane Departures/min					
THC					
BrAC	1	0.030	2.8	0.009	0.0055
THC*BrAC					
Speed Limit	1	0.010	6.8	0.001	<0.0001
Inverse Curvature	1	10.9	5.2	2.1	<0.0001
Intercept	1	1.4	10.3	0.14	<0.0001
Subject	17				
Model df:	20				
Model F-value	19.59				

Error df:	840				
Maximum Lateral Acceleration (Non-Sharp Events)					
THC					
BrAC	1	0.0023	3.5	0.0007	0.0005
THC*BrAC					
Speed Limit	1	0.0012	11.4	0.0001	<0.0001
Inverse Curvature					
Intercept	1	0.091	10.0	0.0091	<0.0001
Subject	17				
Model df:	19				
Model F-value	17.37				
Error df:	2026				
Maximum Lateral Acceleration (Sharp Events)					
THC					
BrAC					
THC*BrAC					
Speed Limit					
Inverse Curvature	1	-1.8	-4.3	0.43	<0.0001
Intercept	1	0.45	17	0.027	<0.0001
Subject	17				
Model df:	18				
Model F-value	8.61				
Error df:	304				

Driving occurred 0.5h after drinking placebo or active alcohol (calculated to produce approximate peak 0.065% BrAC) and inhaling placebo, 2.9% THC, or 6.7% THC vaporized bulk cannabis (500 mg, Volcano® Medic vaporizer). Estimate represents parameter (coefficient) estimate [effect size scaled to the unit] for each factor (negative b indicates the parameter decreases the effect; positive b indicates the parameter increases the overall effect).

Boldface indicates parameter included in the final GLM Select model. All p-values for final overall analysis of variance of model fits were <0.0001.

Abbreviations: DF, degrees of freedom; THC, blood Δ^9-tetrahydrocannabinol concentration; BrAC, breath alcohol concentration

Table 3. GLM Select model estimates for predicted standard deviation of lateral position (SDLP), lane departures/min, and maximum lateral acceleration associated with specific blood Δ^9-tetrahydrocannabinol (THC) concentrations and breath alcohol concentrations (BrAC) during driving

During-Drive Concentration		Standard Deviation of Lateral Position (SDLP)			Lane Departures/min			Maximum Lateral Acceleration (Non-Sharp Events)		
THC (μg/L)	BrAC (g/210L)	Median [range] predicted SDLP (cm)	Difference (cm)	Percent Increase[a] (%)	Median [range] predicted lane departures/min (N)	Difference (N)	Percent Increase[a] (%)	Median [range] predicted maximum lateral acceleration (m/s^2)	Difference (m/s^2)	Percent Increase[a] (%)
0	0	31.4 [24.7-44.8]	--	--	0.38 [0.05-1.95]	--	--	1.17 [0.87-1.54]	--	--
1	0	31.7 [25.0-45.1]	0.26	0.8	0.38 [0.05-1.95]	0	0	1.17 [0.87-1.54]	0	0
2	0	32.0 [25.3-45.4]	0.52	1.6	0.38 [0.05-1.95]	0	0	1.17 [0.87-1.54]	0	0
5	0	32.7 [26.0-46.1]	1.3	4.1	0.38 [0.05-1.95]	0	0	1.17 [0.87-1.54]	0	0
7	0	33.3 [26.5-46.7]	1.8	5.8	0.38 [0.05-1.95]	0	0	1.17 [0.87-1.54]	0	0
10	0	34.0 [27.3-47.4]	2.6	8.2	0.38 [0.05-1.95]	0	0	1.17 [0.87-1.54]	0	0
20	0	36.6 [29.9-50.0]	5.2	16	0.38 [0.05-1.95]	0	0	1.17 [0.87-1.54]	0	0
0	**0.01**	31.9 [25.2-45.3]	0.42	1.3	0.41 [0.08-1.97]	0.026	6.9	1.19 [0.90-1.56]	0.022	1.9
0	**0.02**	32.3 [25.6-45.7]	0.84	2.7	0.43 [0.11-2.00]	0.053	14	1.21 [0.92-1.58]	0.045	3.8
0	**0.05**	33.6 [26.8-47.0]	2.1	6.7	0.51 [0.19-2.08]	0.13	35	1.28 [0.98-1.65]	0.11	9.5
0	**0.08**	34.8 [28.1-48.2]	3.4	11	0.59 [0.26-2.16]	0.21	55	1.35 [1.05-1.72]	0.18	15
0	**0.10**	35.7 [29.0-49.1]	4.2	13	0.64 [0.32-2.21]	0.26	69	1.39 [1.10-1.76]	0.22	19
2	**0.05**	34.1 [27.4-47.5]	2.6	8.4	0.51 [0.19-2.08]	0.13	35	1.28 [0.98-1.65]	0.11	9.5
5	**0.05**	34.9 [28.1-48.3]	3.4	11	0.51 [0.19-2.08]	0.13	35	1.28 [0.98-1.65]	0.11	9.5

Data generated from 18 healthy occasional cannabis smokers 0.5-1.3h after ingesting placebo or active oral alcohol and inhaling placebo or active vaporized bulk cannabis. Values obtained by assessing general linear model (GLM) Select results of each measure at specific THC concentrations and BrAC. All estimates are for speed 55 miles/h (89 km/h), straight road.

[a]Relative to median baseline (blood THC 0 μg/L, BrAC 0 g/210L) value

Table 4. Participant distribution into 3 (placebo, low, high cannabis) x 2 (placebo, alcohol) repeated measures design and results of repeated measures linear mixed model, accounting for achieved Δ^9-tetrahydrocannabinol (THC) blood maximum concentration. Due to inhaled dose self-titration and interindividual variability, some participants are represented multiple times in certain cells (e.g., THC <8.6 µg/L/placebo alcohol) and not at all in others.

Structural problem with analysis by condition	Placebo Cannabis	THC C_{max} <8.6 µg/L (median) "Low"	THC C_{max} >8.6 µg/L (median) "High"
Placebo Alcohol	18 data points 0 repeating points 18 unique cases	17 data points 6 repeating points (same participant falls into this category for low and high administered doses) 11 unique cases	19 data points 7 repeating points (same participant falls under this category for low and high administered doses) 12 unique cases
Active Alcohol	18 data points 0 repeating points 18 unique cases	19 data points 1 repeating point (same participant falls into this category for low and high administered doses) 18 unique cases	17 data points 1 repeating point (same participant falls into this category for low and high administered doses) 16 unique cases
Results of analysis by condition[a]	Standard Deviation of Lateral Position (SDLP)	Lane Departures/min	Maximum Lateral Acceleration (Non-Sharp Events)
$p_{THC\ group\ (P,L,H)}$	0.2801	0.4537	0.2543
$p_{alcohol\ (P,A)}$	0.0673	0.1286	0.0918
$p_{THC\text{-}alcohol}$	0.2398	0.1245	0.4949
$p_{drive\ event}$	<0.0001	<0.0001	<0.0001

[a]Due to unequal cells and resultant invalid statistical assumptions for within-subjects (repeated measures) design and "missing" or duplicate data, linear mixed model analysis (for which resultant p-values are displayed) has low power and uncertain interpretation.

Table 5. Mean (standard deviation) results for standard deviation of lateral control (SDLP), lane departures/min, and maximum lateral acceleration during driving, grouped by achieved THC/alcohol concentration conditions and by administered THC and alcohol dose conditions.

Achieved THC, Alcohol Conditions (THC Grouped by Median Blood Concentration)			Standard Deviation of Lateral Position (SDLP)				Lane Departures/min				Maximum Lateral Acceleration (Non-Sharp Events)			
THC Group	Alcohol Dose	N	Mean (cm)	St Dev (cm)	Difference (cm)	Percent Increase[a] (%)	Mean (N)	St Dev (N)	Difference (N)	Percent Increase[a] (%)	Mean (m/s^2)	St Dev (m/s^2)	Difference (m/s^2)	Percent Increase[a] (%)
Placebo	Placebo	18	28.8	17.8	--	--	0.52	0.71	-	-	0.115	0.080	-	-
<Median (<8.6 µg/L)	Placebo	11	32.3	21.7	3.5	12%	0.69	0.93	0.17	33%	0.112	0.083	-0.003	-3%
>Median (>8.6 µg/L)	Placebo	12	29.8	16.4	1.0	3%	0.54	0.70	0.02	4%	0.110	0.079	-0.005	-4%
Placebo	Active	18	32.3	21.7	3.5	12%	0.74	0.98	0.22	42%	0.130	0.091	0.015	13%
<Median (<8.6 µg/L)	Active	18	34.6	22.0	5.8	20%	0.76	0.90	0.24	46%	0.126	0.086	0.011	10%
>Median (>8.6 µg/L)	Active	16	32.2	17.8	3.4	12%	0.77	0.98	0.25	48%	0.121	0.088	0.006	5%
Administered Dose Conditions			SDLP				Lane Departures/min				Maximum Lateral Acceleration (Non-Sharp Events)			
THC	Alcohol	N	Mean (cm)	St Dev (cm)	Difference (cm)	Percent Increase[a] (%)	Mean (N)	St Dev (N)	Difference (N)	Percent Increase[a] (%)	Mean (m/s^2)	St Dev (m/s^2)	Difference (m/s^2)	Percent Increase[a] (%)
Placebo	Placebo	18	28.8	17.8	-	-	0.52	0.71	-	-	0.115	0.080	-	-
Low	Placebo	18	31.3	20.3	2.5	9%	0.64	0.85	0.12	23%	0.116	0.084	0.001	1%
High	Placebo	18	31.2	19.1	2.4	8%	0.61	0.84	0.09	17%	0.106	0.078	-0.009	-8%
Placebo	Active	18	32.3	19.3	3.5	12%	0.74	0.98	0.22	42%	0.130	0.091	0.015	13%
Low	Active	18	34.2	21.6	5.4	19%	0.73	0.94	0.21	40%	0.123	0.083	0.008	7%
High	Active	18	32.2	17.4	3.4	12%	0.80	0.96	0.28	54%	0.123	0.092	0.008	7%

Data are from 18 healthy occasional cannabis smokers 0.5-1.3h after ingesting placebo or active oral alcohol and inhaling placebo or active (low/2.9%, high/6.7% Δ^9-tetrahydrocannabinol [THC]) vaporized bulk cannabis. Due to the resultant unbalanced design in low- and high-THC conditions imposed by participants' self-titration, statistical analysis of variance could not be conducted by dose condition.

[a]Relative to placebo-placebo condition

Table 6. Blood and oral fluid THC and variability prior to and after driving (N=19) after controlled vaporized active (2.9% THC and 6.7% THC) cannabis with or without alcohol.

Time post-dose (h)		Blood THC (µg/L)				OF THC (µg/L)			
		No Alcohol		Alcohol		No Alcohol		Alcohol	
		2.9%	6.7%	2.9%	6.7%	2.9%	6.7%	2.9%	6.7%
-0.8 (baseline)	Median	0	0	0	0	0.5	0	0	0.6
	range	0-6.2	0-5.4	0-4.9	0-6.3	0-30.7	0-11.7	0-72.9	0-34.2
	Mean (SD)	0.5 (1.5)	0.4 (1.3)	0.5 (1.2)	0.6 (1.5)	4.6 (8.7)	2.6 (4.0)	6.3 (17.0)	4.7 (8.9)
	%CV	284%	332%	245%	282%	191%	157%	272%	189%
0.17 (pre-drive 1)	Median	32.7	42.2	35.3	67.5	848	764	735	952
	range	11.4-66.2	15.2-137	13.0-71.4	18.1-210	32.1-18,230	25.1-23,680	72.9-7,494	22.7-66,200
	Mean (SD)	35.9 (16.7)	56.2 (36.4)	40.5 (18.2)	75.0 (48.1)	2,101 (4,142)	3,220 (5,645)	1,599 (2,005)	7,652 (15,842)
	%CV	46%	65%	45%	64%	197%	175%	125%	207%
0.42 (pre-drive 2)	Median	10.0	13.2	10.6	16.2	--	--	--	--
	range	1.6-17.9	2.4-40.8	5.5-17.4	5.3-43.9				
	Mean (SD)	10.0 (4.5)	16.8 (10.9)	10.4 (3.4)	19.0 (11.9)	--	--	--	--
	%CV	45%	65%	33%	63%	--	--	--	--
1.4 (post-drive 1)	Median	3.7	4.6	3.6	6.2	52.5	91.0	69.5	138
	range	0-10.7	0-14.7	1.4-6.3	1.3-18.4	3.0-662	9.3-1,028	7.0-1,822	5.2-3,940
	Mean (SD)	3.9 (2.3)	5.7 (3.9)	3.6 (1.4)	6.8 (4.6)	91.3 (145)	213 (275)	228 (418)	637 (1,097)
	%CV	59%	69%	39%	68%	159%	129%	184%	172%
2.3 (post-drive 2)	Median	1.9	2.6	1.8	3.2	33.1	46.9	35.4	91.0
	range	0-8.5	0-9.6	0-4.9	0-9.5	1.8-374	1.9-542	8.7-473	1.6-1,541
	Mean (SD)	2.2 (1.8)	3.2 (2.6)	1.8 (1.1)	3.2 (2.5)	47.7 (81.1)	92.1 (128)	86.4 (124)	263 (458)
	%CV	82%	82%	61%	77%	170%	139%	144%	174%

Abbreviations: THC, Δ^9-tetrahydrocannabinol; OF, oral fluid; SD, standard deviation; CV, coefficient of variation



Figure 1. The National Advanced Driving Simulator: A) exterior, dome mounted in room; B) dome interior with car mounted inside; C) view of night-drive simulation.



Figure 2. GLM Select modeled standard deviation of lateral position (SDLP) versus blood Δ^9-tetrahydrocannabinol (THC) concentration (lower x-axis) and versus breath alcohol concentration (BrAC, upper x-axis). Note x-axis scales are different so slopes cannot be directly compared; dotted lines indicate THC concentrations producing equivalent SDLP to 0.02, 0.05, and 0.08g/210L BrAC.



Figure 3. Box plot of maximum blood Δ^9-tetrahydrocannabinol (THC) concentration by administered cannabis (placebo, 0.008% THC; low, 2.9% THC; high, 6.7% THC) and alcohol (placebo, active) doses for 18 participants.

Supplemental Table 1. General Linear Model (GLM) Select results of natural log (ln)-transformed standard deviation of lateral position (SDLP) in 18 volunteer drivers after controlled vaporized cannabis with or without oral alcohol.

ln(SDLP)					
Parameter	DF	ln Estimate (b)	t	Standard Error	p-value
THC	1	0.008	3.79	0.002	0.0002
BrAC	1	0.014	3.30	0.004	0.0010
THC*BrAC					
Speed Limit	1	0.013	17	0.001	<0.0001
Inverse Curvature	1	15	10	1.4	<0.0001
Intercept	1	3.0	48	0.062	<0.0001
Subject	17				
Model df:	21				
Model F-value	26.02				
Error df:	1916				

Driving occurred 0.5h after drinking placebo or active alcohol (calculated to produce approximate peak 0.065% BrAC) and inhaling placebo, 2.9% THC, or 6.7% THC vaporized bulk cannabis (500 mg, Volcano® Medic vaporizer). Estimate represents parameter (coefficient) estimate for each factor (negative b indicates the parameter decreases the effect; positive b indicates the parameter increases the overall effect). The t-values estimate effect size. **Boldface** indicates parameter included in the final GLM Select model of ln(SDLP).
Abbreviations: DF, degrees of freedom; THC, blood Δ^9-tetrahydrocannabinol concentration; BrAC, breath alcohol concentration

Supplemental Table 2. Standard deviation of lateral position (SDLP) associated with specific blood Δ^9-tetrahydrocannabinol (THC) concentrations and breath alcohol concentrations (BrAC) during driving based on transformed ln(SDLP) GLM Select model.

During-Drive Concentration		Standard Deviation of Lateral Position (SDLP)		
THC (µg/L)	BrAC (g/210L)	Median [range] Predicted SDLP (cm)	Difference[a] (cm)	Percent Increase[a] (%)
0	0	26.5 [20.6-40.5]	--	--
1	0	26.8 [20.8-40.8]	0.2	0.8
2	0	27.0 [21.0-41.2]	0.4	1.6
5	0	27.6 [21.5-42.2]	1.1	4.2
7	0	28.1 [21.8-42.9]	1.6	5.9
10	0	28.8 [22.4-43.9]	2.3	8.5
20	0	31.2 [24.3-47.7]	4.7	18
0	**0.01**	26.9 [20.9-41.1]	0.4	1.4
0	**0.02**	27.3 [21.2-41.7]	0.8	2.9
0	**0.05**	28.5 [22.1-43.5]	2.0	7.4
0	**0.08**	29.7 [23.1-45.4]	3.2	12
0	**0.10**	30.6 [23.8-46.7]	4.1	15
2	**0.05**	29.0 [22.5-44.2]	2.4	9.1
5	**0.05**	29.7 [23.1-45.3]	3.1	12

Data generated from 18 healthy occasional cannabis smokers 0.5-1.3h after ingesting placebo or active oral alcohol and inhaling placebo or active vaporized bulk cannabis. Values obtained by assessing GLM Select results at specific THC concentrations and BrAC, speed limit 55 miles/h (89 km/h), straight road.

[a]Relative to median.



Supplemental Figure 1. Median and individual subject model-predicted standard deviation of lateral position (SDLP) for various blood Δ^9-tetrahydrocannabinol (THC) concentrations (A) and breath alcohol concentrations (BrAC) (B). Data generated from 18 healthy occasional cannabis smokers 0.5-1.3h after ingesting placebo or active oral alcohol and inhaling placebo or active vaporized bulk cannabis. Values obtained by assessing GLM Select results at specific THC concentrations and BrAC, speed limit 55 miles/h (89 km/h), straight road